Please login to the form below

Not currently logged in
Email:
Password:

Merck suspends Stimuvax programme

Merck has temporarily suspended its Stimuvax clinical programme after a patient developed encephalitis, an acute inflammation of the brain

Merck has temporarily suspended its Stimuvax (BLP25 liposome vaccine) clinical programme on a worldwide scale after a patient developed encephalitis, an acute inflammation of the brain.

The German pharmaceutical company has said that "effective immediately" all enrollments into trials and treatment of patients in current trials will be put on hold.

The decision was taken "in alignment with the US Food and Drug Administration's (FDA) clinical hold placed on the Investigational New Drug (IND) application for Stimuvax," according to Merck in a statement.

The Stimuvax vaccine is currently being tested in both phase II and phase III clinical trials for the treatment of non-small cell lung carcinoma (NSCLC) and breast cancer after being granted fast-track status in September 2004 by the FDA.

The patient who developed encephalitis was participating in a phase II exploratory trial using the vaccine in patients with multiple myeloma. This trial involved an intensified schedule of low-dose cyclophosphamide, a treatment not used in other Stimuvax studies.

The affected ongoing trials affected by the suspension include the NSCLC studies START and INSPIRE and the breast cancer study STRIDE.

"The company considers patient safety of paramount importance," said Merck "and will continue to work closely with the regulatory authorities, particularly with the FDA, to evaluate the implications of the adverse reaction on the clinical development programme for Stimuvax and determine the most suitable course of action."

23rd March 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...
image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...

Infographics